Autopsy report · NCT02491411
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
Cause of deathSlow enrollment
“The study is terminated due to lower enrollment”
Life of this trial
- Registered 3 months before it started.
- Ran for about 2 years 6 months before it stopped.
- 5 participants enrolled.
- Results were posted on the registry 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Na
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Sponsor type
- University, hospital or other
- Conditions
- Hormone-Resistant Prostate Cancer; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IV Prostate Cancer
- Interventions
- Dexamethasone; Enzalutamide; Laboratory Biomarker Analysis; Quality-of-Life Assessment
- Participants
- 5
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Evaluation of the Consumption of a Probiotic on the Load of S. Agalactiae.
“The study was terminated due to low enrollment” - Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
“Study was terminated due to low enrollment” - A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension
“Study was terminated due to poor enrollment” - Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
“Study terminated due to low enrollment.” - Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
“Study has been terminated and replaced due to low enrollment.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.